Pharmacogenomics

From Self-sufficiency
Jump to: navigation, search

Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. By doing so, pharmacogenomics aims to develop rational means to optimise drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects. Such approaches promise the advent of "personalized medicine"; in which drugs and drug combinations are optimized for each individual's unique genetic makeup.[1]

Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs.

Pharmacogenomics is being used all critical illnesses like cancer, cardio vascular disorders, AIDS, TB, Asthma, Diabetes.

In Cancer, pharmacogenomics tests are used to identify which patient will have toxicity from commonly used cancer drugs and identify which patient will not respond to commonly used cancer drug. Over the last couple of years, pharmacogenomics is also as companion diagnostics, meaning tests being bundled with drugs. Two good examples are K-ras test with cituximab and EGFR test with Gefitinib.

In Cardio vascular disorders, the main concern is response to warfarin, clopidogrel, beta blockers, statins etc.

See also


References

  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.

External links

ar:علم الصيدلة الجيني

ca:Farmacogenòmica de:Pharmakogenomik es:Farmacogenómica fr:Pharmacogénomique ko:약학유전체학 is:Lyferfðamengjafræði it:Farmacogenomica ja:ゲノム薬理学 pl:Farmakogenomika ru:Фармакогеномика sr:Farmakogenomika th:ฟาร์มาโคยีโนมิกส์